ArticleFrontiers in microbiology2016
SLPW: A Virulent Bacteriophage Targeting Methicillin-Resistant Staphylococcus aureus In vitro and In vivo.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Prophage landscapes in clinical MRSA: safety profiling and discovery of Lys81, a broad-spectrum bacteriolytic enzyme.Frontiers in microbiology · 2026Article
- Phenotypic and genomic characterization of vB_SauP-INT105, an exopolysaccharide depolymerase-encoding lytic short-tailed phage with antibiofilm activity againstFrontiers in microbiology · 2026Article
- Genomic and functional characterization of a novel lytic phage vB-AbaM-fThrA with anti-biofilm activity against CR-MDR Acinetobacter baumannii.BMC microbiology · 2025Article
- Utilizing the effectiveness of phage cocktail to combat Shigella and Salmonella infections and their polymicrobial biofilm control activity.BMC microbiology · 2025Article
- Characterization of Newly IsolatedMicroorganisms · 2025Article
- Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.International journal of molecular sciences · 2025Review
- Article
- Biological function identification of phage holin Hol-4086 and treatment ofFrontiers in microbiology · 2025Article
- Pharmacodynamic Evaluation of Phage Therapy in Ameliorating ETEC-Induced Diarrhea in Mice Models.Microorganisms · 2024Article
- Characterization and complete genome sequence of highly lytic phage active against methicillin-resistant Staphylococcus aureus (MRSA) isolated from Egypt.Virology journal · 2024Article
- Article
- The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.Virology journal · 2024Review
- A NewPharmaceutics · 2024Article
- Therapeutics and prophylactic efficacy of novel lytic Escherichia phage vB_EcoS_PJ16 against multidrug-resistant avian pathogenic E. coli using in vivo study.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- In vitro evaluation of two novel Escherichia bacteriophages against multiple drug resistant avian pathogenic Escherichia coli.BMC infectious diseases · 2024Article
- Bacteriophage vB_SepP_134 and Endolysin LysSte_134_1 as Potential Staphylococcus-Biofilm-Removing Biological Agents.Viruses · 2024Article
- Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.European journal of microbiology & immunology · 2024Review
- Biological characteristics of the bacteriophage LDT325 and its potential application against the plant pathogenFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus (S. aureus) is a Gram-positive pathogen causing a variety of infections in humans and animals. Extensive use of antibiotics has led to the emergence of methicillin-resistant S. aureus (MRSA). As an alternative antibacterial agent against drug-resistant S. aureus, a lytic phage, designated SLPW, was isolated from fecal sewage in a pig farm. The SLPW was morphologically classified under Podoviridae and contains a double-stranded DNA genome. The genome of SLPW was 17,861 bp (29.35% G+C) containing 20 open reading frames and lacked regions encoding lysogeny-related integrase gene and cI repressor gene. Phage SLPW showed a broad host range and high efficiency of plating against various types of S. aureus. One-step growth curve showed a short latency period (10 min) and a long lytic period (120 min). Phage SLPW remained stable under a wide range of temperatures or pH and was almost unaffected in chloroform or ultraviolet light. Further, it efficiently lysed MRSA strains in vitro and in vivo. Intraperitoneal phage administration at 1 h post-infection cured the mice and reduced the bacterial expression of inflammatory cytokines in mice. Specifically, the phage SLPW displayed a wide antibacterial spectrum. It was therapeutically effective against intra-abdominal infection in mice harboring different multilocus sequence typing (MLST) types of S. aureus strains. Therefore, phage SLPW is a potential therapeutic agent against MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.